ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,537 | -60.2% | 31,160 | -43.6% | 0.00% | – |
Q2 2023 | $76,730 | -24.1% | 55,202 | -13.2% | 0.00% | – |
Q1 2023 | $101,110 | -30.8% | 63,591 | +171.0% | 0.00% | – |
Q4 2022 | $146,162 | +53.9% | 23,461 | +66.6% | 0.00% | – |
Q3 2022 | $95,000 | -8.7% | 14,084 | -14.4% | 0.00% | – |
Q2 2022 | $104,000 | +62.5% | 16,454 | +18.9% | 0.00% | – |
Q1 2022 | $64,000 | -80.2% | 13,844 | -78.6% | 0.00% | – |
Q4 2021 | $323,000 | -22.4% | 64,742 | +87.6% | 0.00% | – |
Q3 2021 | $416,000 | -63.0% | 34,516 | -35.0% | 0.00% | – |
Q2 2021 | $1,124,000 | -39.8% | 53,140 | -20.2% | 0.00% | -100.0% |
Q1 2021 | $1,867,000 | +403.2% | 66,575 | +366.2% | 0.00% | – |
Q4 2020 | $371,000 | -57.6% | 14,279 | -39.4% | 0.00% | – |
Q3 2020 | $875,000 | -69.7% | 23,558 | -58.1% | 0.00% | -100.0% |
Q2 2020 | $2,886,000 | -32.9% | 56,248 | -58.8% | 0.00% | -50.0% |
Q1 2020 | $4,302,000 | +11.0% | 136,423 | +110.0% | 0.00% | +100.0% |
Q4 2019 | $3,874,000 | +835.7% | 64,965 | +475.2% | 0.00% | – |
Q3 2019 | $414,000 | -64.0% | 11,295 | -54.4% | 0.00% | – |
Q2 2019 | $1,151,000 | +15.4% | 24,747 | -0.3% | 0.00% | – |
Q1 2019 | $997,000 | -88.3% | 24,821 | -86.6% | 0.00% | -100.0% |
Q4 2018 | $8,531,000 | +171.2% | 185,442 | +161.5% | 0.00% | +300.0% |
Q3 2018 | $3,146,000 | +100.9% | 70,904 | +77.4% | 0.00% | 0.0% |
Q2 2018 | $1,566,000 | -80.5% | 39,963 | -64.0% | 0.00% | -66.7% |
Q1 2018 | $8,020,000 | +45.2% | 110,882 | +32.1% | 0.00% | +50.0% |
Q4 2017 | $5,524,000 | +5.8% | 83,907 | -19.5% | 0.00% | 0.0% |
Q3 2017 | $5,223,000 | -25.8% | 104,191 | -31.5% | 0.00% | -50.0% |
Q2 2017 | $7,038,000 | +97.1% | 152,061 | +50.4% | 0.00% | +100.0% |
Q1 2017 | $3,571,000 | +489.3% | 101,131 | +108.9% | 0.00% | – |
Q4 2016 | $606,000 | -11.4% | 48,419 | -1.9% | 0.00% | – |
Q3 2016 | $684,000 | +388.6% | 49,373 | +250.6% | 0.00% | – |
Q2 2016 | $140,000 | -26.3% | 14,081 | +25.2% | 0.00% | – |
Q1 2016 | $190,000 | -94.0% | 11,247 | -92.1% | 0.00% | -100.0% |
Q4 2015 | $3,183,000 | +114.8% | 143,012 | +127.7% | 0.00% | +100.0% |
Q3 2015 | $1,482,000 | +39.0% | 62,797 | +381.4% | 0.00% | 0.0% |
Q2 2015 | $1,066,000 | +1737.9% | 13,045 | +1993.9% | 0.00% | – |
Q1 2015 | $58,000 | -69.3% | 623 | -86.6% | 0.00% | – |
Q4 2014 | $189,000 | – | 4,657 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |